Malignant neoplasm of paraurethral glands
ICD-10 C68.1 is a billable code used to indicate a diagnosis of malignant neoplasm of paraurethral glands.
Malignant neoplasm of the paraurethral glands, also known as Skene's glands, is a rare form of cancer that arises from the paraurethral glands located near the female urethra. These glands are responsible for secreting fluid that contributes to lubrication during sexual arousal. The malignancy can present with symptoms such as abnormal vaginal bleeding, pelvic pain, or urinary symptoms, including dysuria or urinary retention. Diagnosis typically involves imaging studies, such as ultrasound or MRI, and a biopsy to confirm malignancy. Staging of the cancer is crucial for determining the extent of disease and guiding treatment options. The staging system may include assessments of local invasion, lymph node involvement, and distant metastasis. Surgical management often involves excision of the tumor, which may include partial or complete urethrectomy, depending on the tumor's size and extent. Adjuvant therapies, such as radiation or chemotherapy, may be considered based on the tumor's characteristics and staging.
Detailed surgical notes, pathology reports, and imaging results are essential for accurate coding.
Diagnosis and management of paraurethral gland tumors, including surgical interventions and follow-up care.
Urologists must ensure comprehensive documentation of tumor characteristics and staging to support coding.
Oncologists should provide detailed treatment plans, including chemotherapy or radiation therapy notes.
Management of advanced paraurethral gland malignancies requiring multidisciplinary treatment.
Oncology documentation must clearly outline the rationale for treatment choices based on staging.
Used when excising a malignant tumor from the paraurethral glands.
Surgical notes must detail the extent of excision and any complications.
Urologists should document the rationale for surgical intervention based on tumor staging.
Common symptoms include abnormal vaginal bleeding, pelvic pain, urinary retention, and dysuria. Patients may also experience changes in urinary habits.
